Quantifying and Qualifying the Preventive Effects of Acute-Phase Cognitive Therapy: Pathways to Personalizing Care

Robin B. Jarrett, Abu Minhajuddin, Jeffrey R. Vittengl, Lee Anna Clark, Michael E. Thase

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17%) and higher risk (n = 241; 83%). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9% = lower risk; 22.1% = higher risk; log-rank ?2 = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent "dosing" of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended. (PsycINFO Database Record

Original languageEnglish (US)
JournalJournal of Consulting and Clinical Psychology
DOIs
StateAccepted/In press - Dec 14 2015

Fingerprint

Cognitive Therapy
Recurrence
Major Depressive Disorder
Pathway
Therapy
Fluoxetine
Kaplan-Meier Estimate
Outpatients
Therapeutics
Placebos
Maintenance
Depression

Keywords

  • Cognitive therapy
  • Depression
  • Predictors of outcomes
  • Recurrence
  • Relapse

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Arts and Humanities (miscellaneous)

Cite this

Quantifying and Qualifying the Preventive Effects of Acute-Phase Cognitive Therapy : Pathways to Personalizing Care. / Jarrett, Robin B.; Minhajuddin, Abu; Vittengl, Jeffrey R.; Clark, Lee Anna; Thase, Michael E.

In: Journal of Consulting and Clinical Psychology, 14.12.2015.

Research output: Contribution to journalArticle

@article{18b2c56910e34ec28c5ed0b72d5b8a5e,
title = "Quantifying and Qualifying the Preventive Effects of Acute-Phase Cognitive Therapy: Pathways to Personalizing Care",
abstract = "Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17{\%}) and higher risk (n = 241; 83{\%}). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9{\%} = lower risk; 22.1{\%} = higher risk; log-rank ?2 = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent {"}dosing{"} of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended. (PsycINFO Database Record",
keywords = "Cognitive therapy, Depression, Predictors of outcomes, Recurrence, Relapse",
author = "Jarrett, {Robin B.} and Abu Minhajuddin and Vittengl, {Jeffrey R.} and Clark, {Lee Anna} and Thase, {Michael E.}",
year = "2015",
month = "12",
day = "14",
doi = "10.1037/ccp0000069",
language = "English (US)",
journal = "Journal of Consulting and Clinical Psychology",
issn = "0022-006X",
publisher = "American Psychological Association Inc.",

}

TY - JOUR

T1 - Quantifying and Qualifying the Preventive Effects of Acute-Phase Cognitive Therapy

T2 - Pathways to Personalizing Care

AU - Jarrett, Robin B.

AU - Minhajuddin, Abu

AU - Vittengl, Jeffrey R.

AU - Clark, Lee Anna

AU - Thase, Michael E.

PY - 2015/12/14

Y1 - 2015/12/14

N2 - Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17%) and higher risk (n = 241; 83%). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9% = lower risk; 22.1% = higher risk; log-rank ?2 = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent "dosing" of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended. (PsycINFO Database Record

AB - Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17%) and higher risk (n = 241; 83%). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9% = lower risk; 22.1% = higher risk; log-rank ?2 = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent "dosing" of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended. (PsycINFO Database Record

KW - Cognitive therapy

KW - Depression

KW - Predictors of outcomes

KW - Recurrence

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84949870333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949870333&partnerID=8YFLogxK

U2 - 10.1037/ccp0000069

DO - 10.1037/ccp0000069

M3 - Article

C2 - 26654211

AN - SCOPUS:84949870333

JO - Journal of Consulting and Clinical Psychology

JF - Journal of Consulting and Clinical Psychology

SN - 0022-006X

ER -